Anne Ploquin1, Farid Zerimech2, Fabienne Escande2, Antoine Adenis3, Claire Giraud4, Laurent Gasnault5, Vincent Bourgeois6, Christophe Desauw7, Mohamed Hebbar8. 1. Department of Medical Oncology, University Hospital, Lille, France anne.ploquin@chru-lille.fr. 2. Biomolecular platform, University Hospital, Lille, France. 3. Department of Urodigestive Oncology, Oscar Lambret Center, Lille, France. 4. Department of Oncology, Leonard de Vinci Hospital, Douai, France. 5. Department of Oncology, Joliot Curie Center, Boulogne-sur-mer, France. 6. Department of Medical Oncology, University Hospital, Lille, France Department of Oncology, General Hospital, Boulogne-sur-mer, France. 7. Department of Medical Oncology, University Hospital, Lille, France Department of Oncology, General Hospital, Calais, France. 8. Department of Medical Oncology, University Hospital, Lille, France.
Abstract
BACKGROUND/AIM: We previously identified three clinical predictive factors of efficacy of cetuximab-irinotecan. Here, we analyzed the clinical characteristics of patients with metastatic colorectal cancer (CRC) in order to detect potent correlations with KRAS mutations. PATIENTS AND METHODS: We conducted a retrospective, multicenter study between 2008 and 2012. We included patients with metastatic colorectal adenocarcinomas, previously treated by irinotecan, and with an available KRAS mutation test. RESULTS: We included 299 patients. The median age was 60 years; the median number of metastatic sites was 2. One hundred and eight patients (36.1%) had a previous objective response to irinotecan. The median interval between diagnosis and irinotecan discontinuation was 1.94 years. A KRAS mutation was detected in 133 patients (44.5%). In univariate and multivariate analyses, none of the assessed factors was associated with the presence of a KRAS mutation. CONCLUSION: No easily clinically assessable parameter was significantly associated with KRAS mutations in patients with colorectal cancer. Copyright
BACKGROUND/AIM: We previously identified three clinical predictive factors of efficacy of cetuximab-irinotecan. Here, we analyzed the clinical characteristics of patients with metastatic colorectal cancer (CRC) in order to detect potent correlations with KRAS mutations. PATIENTS AND METHODS: We conducted a retrospective, multicenter study between 2008 and 2012. We included patients with metastatic colorectal adenocarcinomas, previously treated by irinotecan, and with an available KRAS mutation test. RESULTS: We included 299 patients. The median age was 60 years; the median number of metastatic sites was 2. One hundred and eight patients (36.1%) had a previous objective response to irinotecan. The median interval between diagnosis and irinotecan discontinuation was 1.94 years. A KRAS mutation was detected in 133 patients (44.5%). In univariate and multivariate analyses, none of the assessed factors was associated with the presence of a KRAS mutation. CONCLUSION: No easily clinically assessable parameter was significantly associated with KRAS mutations in patients with colorectal cancer. Copyright
Authors: Adriana Rico; Lori A Pollack; Trevor D Thompson; Mei-Chin Hsieh; Xiao-Cheng Wu; Jordan J Karlitz; Dee W West; John M Rainey; Vivien W Chen Journal: J Cancer Res Ther (Manch) Date: 2017-01-30